Updated 3:40 p.m. April 30, 2024. The Drug Enforcement Administration (DEA) will reclassify cannabis as a Schedule III drug under the Controlled Substances Act, a move that marks a significant shift in federal drug policy. This decision comes after years of advocacy from cannabis proponents who argue that the current scheduling of marijuana as a Schedule I drug is outdated and inaccurate.
For the first time, the Drug Enforcement Administration has called for 'botanical cannabis' to be reclassified under federal law. This reclassification would mean that cannabis is recognized as having medical benefits and a lower potential for abuse compared to other controlled substances.
In a milestone move, the Drug Enforcement Administration is calling for cannabis to be reclassified under federal law, signaling a potential turning point in the ongoing debate over marijuana legalization. The DEA's decision to move marijuana to Schedule III would put it in the same category as substances like ketamine and anabolic steroids.
The DEA is reportedly moving to reclassify marijuana as a less dangerous drug in a monumental decision that could have far-reaching implications for the cannabis industry. This reclassification could open up new opportunities for medical research, access to cannabis-based medications, and potentially even federal legalization of recreational marijuana.
Cannabis stocks were up sharply on Tuesday on a report by the Associated Press that the U.S. Drug Enforcement Administration is poised to reclassify marijuana as a Schedule III drug. Investors and industry insiders are closely watching the developments, anticipating potential changes in regulations and market dynamics.
(CNN) — The Biden administration will move Tuesday to reclassify marijuana as a lower-risk substance, a person familiar with the plans told. This move is seen as a significant step towards reforming federal drug policies and addressing the disparities in how marijuana is treated under the law.
Click in for more news from The Hill {beacon} Health Care Health Care The Big Story White House moving to reschedule marijuana The Biden administration's decision to support the reclassification of marijuana is a major win for advocates and supporters of cannabis reform. The move is expected to have ripple effects across various sectors, from healthcare to criminal justice.
Cannabis stocks surged Tuesday on the news that the U.S. Drug Enforcement Administration intends to reclassify marijuana to Schedule 3. This announcement has sparked excitement and speculation within the industry, as companies and investors prepare for potential shifts in regulations and market dynamics.
The Drug Enforcement Administration's (DEA) decision to reschedule marijuana is being met with relief, elation, commendations—and criticism from various stakeholders. While some applaud the move as a step towards more sensible drug policy, others raise concerns about the implications of reclassifying cannabis and the potential impact on public health and safety.
